|Bid||346.95 x 1300|
|Ask||349.00 x 1200|
|Day's range||345.00 - 370.80|
|52-week range||58.81 - 464.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||09 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||332.87|
Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination seriesReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to le
Yahoo Finance’s Anjalee Khemlani reports the latest on the FDA’s decision regarding covid booster shots.
Dr. Hiral Tipirneni, Emergency Medicine Physician, joins Yahoo Finance Live to discuss the latest on the coronavirus pandemic.